Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TCBP
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.22
+499068%
2.9K
vs -0.59
Q3.22
N/A
-0.07
vs -0.85
Q4.22
N/A
-0.08
vs -0.67
Q1.23
N/A
-0.02
vs -302.80
Q2.23
-100%
0
vs 2.9K
Q3.23
N/A
-0.02
vs -0.07
Q4.23
N/A
-0.02
vs -0.08
Q1.24
N/A
-2.80
vs -0.02
Q2.24
N/A
NA
vs 0
Q3.24
+5862%
1.18
vs -0.02
Sales Growth
YoY
Current
Estimates
Q1.22
NA
494.7K vs 494.7K
Q2.22
NA
494.7K vs 494.7K
Q3.22
+189%
1.4M vs 494.7K
Q4.22
+189%
1.4M vs 494.7K
Q1.23
-100%
NA vs 494.7K
Q2.23
-100%
NA vs 494.7K
Q3.23
-100%
NA vs 1.4M
Q4.23
-100%
NA vs 1.4M
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Return on Equity
QoQ
Q3.22
-276%
-2.76
vs 0.25
Q4.22
-276%
-2.76
vs -2.76
Q1.23
-192%
-1.92
vs -2.76
Q2.23
+11%
0.11
vs -1.92
Q3.23
-117%
-1.17
vs 0.11
Q4.23
-117%
-1.17
vs -1.17
Q1.24
-307%
-3.07
vs -1.17
Q2.24
-99%
-0.99
vs -3.07
Institutionnal Ownership
QoQ
Q1.22
8
8
vs NA
NA
Q2.22
5
5
vs 8
-37%
Q3.22
5
5
vs 5
NA
prnewswire.com
8 hours ago
prnewswire.com
8 hours ago
prnewswire.com
10 hours ago
prnewswire.com
10 hours ago
Relative Strength
TCBP
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
Relative Strenght
3
Volume Buzz
1461%
Earning Acce
Yes
Dist 52w H.
100%Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available